In combination w/ capecitabine for the treatment of patients w/ advanced or metastatic breast cancer whose tumours overexpress ErbB2 (HER2/neu) & progressed after treatment w/ trastuzumab. In combination w/ trastuzumab for the treatment of patients w/ metastatic breast cancer whose tumours overexpress ErbB2 (HER2/neu) & progressed after treatment of trastuzumab therapy. In combination w/ paclitaxel for the treatment of patients w/ metastatic breast cancer whose tumours overexpress ErbB2 (HER2/neu). In combination w/ an aromatase inhibitor for the treatment of postmenopausal woman w/ hormone receptor-positive, ErbB2 (HER2/neu) overexpressing advanced & metastatic breast cancer.
In combination w/ capecitabine 1,250 mg once daily continuously & capecitabine 2,000 mg/m2/day in 2 doses 12 hr apart on days 1-14 in 21-day cycle. In combination w/ trastuzumab 1,000 mg once daily continuously & trastuzumab 4 mg/kg IV loading dose, followed by 2 mg/kg IV wkly. In combination w/ paclitaxel 1,500 mg once daily continuously & paclitaxel 80 mg/m2 on days 1, 8 & 15 in 28-day schedule, alternatively, paclitaxel may be given at a dose of 175 mg/m2 every 21 days. In combination w/ an aromatase inhibitor 1,500 mg once daily continuously & letrozole 2.5 mg once daily.
Conditions that could impair left ventricular function. Evaluate left ventricular ejection fraction (LVEF) prior to treatment. Monitor liver function & pulmonary symptoms indicative of ILD/pneumonitis. Moderate or severe hepatic impairment. Pregnancy & lactation. Childn.
L01EH01 - lapatinib ; Belongs to the class of human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors. Used in the treatment of cancer.
Sign Out
